Analytical Data
-
Gene name
RDX
- Application
-
Alternative Names
DFNB24; Deafness,Autosomal Recessive 24
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35241
-
Expression Region
Ile5~Arg295
-
Molecular Weight
37kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RDX, or Rhodococcus-like protein, has garnered interest in the field of biotechnology and molecular biology due to its unique biochemical properties and potential applications. Originally identified in the bacterial genus Rhodococcus, RDX is known for its role in bioremediation, specifically its ability to degrade various environmental pollutants, including explosives and industrial chemicals. Research into RDX recombinant proteins has expanded significantly, driven by the need for sustainable solutions to environmental contamination and the development of biosensors. By engineering RDX proteins through recombinant DNA technology, scientists aim to enhance their stability, catalytic efficacy, and substrate specificity. This allows for more effective detoxification processes. Furthermore, RDX recombinant proteins offer promising avenues for therapeutic applications, such as enzyme replacement therapies and drug delivery systems. The ongoing studies also delve into the structural biology of RDX, providing insights into its mechanism of action and enabling the design of more efficient enzymes. Ultimately, the multifaceted research on RDX recombinant proteins combines environmental science, biochemistry, and biotechnology, reflecting a broader trend towards leveraging biological systems for solving pressing ecological and health-related challenges. As the demand for sustainable practices grows, RDX research represents a vital intersection of innovation and ecological stewardship.
